Gingko biloba Extract Ameliorates Colonic Inflammation in DSS-induced Model of Colitis in Mice

초록

Ulcerative colitis (UC) is a serious gastrointestinal tract disease characterized by recurrent chronic inflammation andmucosal damage of the gastrointestinal tract. The conventional therapies of choice are anti-inflammatory agents, steroidsand anti-TNF-α therapy. However, inherent limitations in these therapies have steered many UC patients to supplementexisting therapies with alternative medicinal products. In the current study, we tested the efficacy of Gingko bilola extract(EGb 761) in abating colonic inflammation in a DSS-induced murine model of colitis. C57BL/6 mice were administered2% DSS in the drinking water for 7 days, then regular water for 7 days, and then 2% DSS for an additional 7 days. EGb761 (1 mg/dose) was oral gavaged daily for the duration of the experiment. At the termination of the experiment, micetreated with EGb+DSS showed higher body weight, lower spleen weight and longer colon length compared to micetreated with DSS alone. HE-stained colon tissues also exhibited less histologic inflammation in mice treated with EGb+DSS mice compared to mice treated with DSS alone. The serum levels inflammatory cytokines, KC and TNF-α, werealso decreased in mice treated with EGb+DSS compared to mice treated with DSS alone. Finally, addition of EGb 761to TNF-α treated colonic cell line (HT29/c1) decreased secretion of IL-8 in vitro. These results collectively suggest thatEGb 761 abates induction of colitis in DSS-induced model of colitis in mice.

키워드